Clinical Trial Participation

We expect to commence a Phase 3 trial of RT-100 AC6 gene transfer for patients with heart failure and reduced left ventricular ejection fraction across 60 medical centers in the United States. Additional details on the clinical trial, known as FLOURISH, are available on ClinicalTrials.gov (NCT03360448).

We will provide updates on future clinical trials of all of our gene and peptide therapy candidates as they become available.